In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML) aged >60 years remains a matter of debate, notably when performed in first complete remission (CR1). To clarify this issue, the French Innovative Leukemia Organization (FIL...

Descripción completa

Detalles Bibliográficos
Autores principales: Devillier, Raynier, Forcade, Edouard, Garnier, Alice, Guenounou, Sarah, Thepot, Sylvian, Guillerm, Gaelle, Ceballos, Patrice, Hicheri, Yosr, Dumas, Pierre-Yves, Peterlin, Pierre, Hunault-Berger, Mathilde, Béné, Marie-Christine, Bouvier, Anne, Chevallier, Patrice, Blaise, Didier, Vey, Norbert, Pigneux, Arnaud, Récher, Christian, Huynh, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941467/
https://www.ncbi.nlm.nih.gov/pubmed/34525180
http://dx.doi.org/10.1182/bloodadvances.2021004435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941467/
https://www.ncbi.nlm.nih.gov/pubmed/34525180
http://dx.doi.org/10.1182/bloodadvances.2021004435

Ejemplares similares